Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations

被引：0
|
作者：
Cho, B. C. [1 ]
Lu, S. [2 ]
Lee, M. A. [3 ]
Song, Z. [4 ]
Park, J. J. W. [5 ]
Lim, S. M. [6 ]
Li, Z. [2 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [10 ,12 ]
Liu, A. [11 ]
Chen, C. [12 ]
Wang, J. [12 ]
Chen, J. [12 ]
Wang, A. [12 ]
Zhang, J. [10 ,12 ]
Chen, Z. G. [12 ]
Mok, T. S. K. [13 ]
Johnson, M. L. [14 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[3] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea
[4] Zhejiang Canc Hosp, Phase Clin Trial Ward 1, Hangzhou, Peoples R China
[5] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept, Sydney, NSW, Australia
[6] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, GI Oncol, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[12] D3 Bio, Clin Dev Dept, Shanghai, Peoples R China
[13] Prince Wales Hosp, Li Ka Shing Specialist Clin, Clin Oncol Dept, Hong Kong, Peoples R China
[14] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
615MO
引用
收藏
页码：S493 / S493
页数：1
相关论文
共 50 条
  • [1] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
  • [2] Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors
    Hong, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 612 - 614
  • [3] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [4] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [5] LANDSCAPE OF KRAS G12C MUTATIONS IN GENITOURINARY MALIGNANCIES
    Rebecca, Sager A.
    Michael, Basin F.
    Hanan, Goldberg
    Jeffrey, Ross S.
    Gennady, Bratslavsky
    Joseph, Jacob M.
    Petros, Grivas
    Andrea, Necchi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S69 - S69
  • [6] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [7] Targeting KRAS G12C mutations in colorectal cancer
    Zhao, Ming-He
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [8] Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
    Wang, Judy
    Martin-Romano, Patricia
    Cassier, Philippe
    Johnson, Melissa
    Haura, Eric
    Lenox, Laurie
    Guo, Yue
    Bandyopadhyay, Nibedita
    Russell, Michael
    Shearin, Elizabeth
    Lauring, Josh
    Dahan, Laetitia
    ONCOLOGIST, 2022, 27 (07): : 536 - +
  • [9] A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress).
    Ammakkanavar, Natraj Reddy
    Call, Justin
    Shimizu, Toshio
    Kuboki, Yasutoshi
    Liu, Shiyao
    Willard, Melinda D.
    Axelson, Michael
    Heist, Rebecca S.
    Patnaik, Amita
    CANCER RESEARCH, 2022, 82 (12)
  • [10] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
    Li, Jian
    Zhao, Jun
    Cao, Baoshan
    Fang, Jian
    Li, Xiaoyan
    Wang, Mengzhao
    Ba, Yi
    Li, Xingya
    Li, Zhihua
    Liu, Zhe
    Wang, Yongsheng
    Cheng, Ying
    Bai, Chunmei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345